Article

Sotrovimab Retains Activity Against SARS-CoV-2 Omicron Variant BQ.1.1 in a Nonhuman Primate Model

2023-04-06

Abstract excerpt

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 983b5ab0-544b-5552-9fe0-b2c0b0807ecf
DOI: 10.2139/ssrn.4408500

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sotrovimab Retains Activity Against SARS-CoV-2 Omicron Variant BQ.1.1 in a Nonhuman Primate ModelDOI 10.2139/ssrn.4408500Read

Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate modelSemantic proximity Read

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineagesSemantic proximity Read

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster modelSemantic proximity Read

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster modelSemantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity Read

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSemantic proximity Read

<i>In vivo</i> virological efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineagesSemantic proximity Read

Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 InfectionSemantic proximity Read

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolateSemantic proximity Read